On 28 June, Glenmark Pharmaceuticals Ltd acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the US.

The wholly-owned subsidiary company of Glenmark Pharmaceuticals Inc includes USA-approved abbreviated new drugs applications (ABDAs) for famotidine tablets. The company says that the medicine of 10mg and 20mg is used to treat and prevent ulcers in the stomach and intestine.

However, the company did not disclose the financial statement due to confidential data.

Also, Glenmark Pharmaceuticals has acquired ANDAs medicine for anti-allergy cetirizine hydrochloride tablets with 5mg and 10mg indigestion, heartburn and acid reflux treatment drug Lansoprazole delayed-release capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent indicated for allergic conjunctivitis and allergic rhinitis, in the US.

“The over-the-counter market has long been an important segment of Glenmark’s portfolio worldwide. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines,” Glenmark Pharmaceuticals Inc, USA, President Sanjeev Krishan said.